NCT00910728

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 65 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 25 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This study is being conducted to test study drug AZD1480 to see how it may work to treat myeloproliferative diseases. The main purpose of this study is to determine the safety and tolerability of AZD1480. This is the first time the drug has been given to humans and is classed as a first time in man study. Its main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. The study will also assess the blood levels and action of AZD1480 in the body over a period of time and will indicate whether the drug has a therapeutic effect on myeloproliferative diseases.

Conditions

• Primary Myelofibrosis (PMF)
• Post-Polycythaemia Vera
• Essential Thrombocythaemia Myelofibrosis

Interventions

Type	Name	Description
DRUG	AZD1480	Oral capsule 2.5 mg, 10 mg and 40 mg

Timeline

• Start date: 2009-05-01
• Primary completion: 2012-03-01
• Completion: 2014-08-01
• First posted: 2009-06-01
• Last updated: 2017-04-24
• Results posted: 2017-04-24

Locations

3 sites across 2 countries: United States, France